O'Loughlin Steve 4

4 · Actinium Pharmaceuticals, Inc. · Filed Mar 8, 2018

Insider Transaction Report

Form 4
Period: 2018-03-06
O'Loughlin Steve
Chief Financial Officer
Transactions
  • Other

    Common Stock

    2018-03-06$0.50/sh+10,000$5,00013,500 total
  • Other

    Series B Warrants

    2018-03-06$0.50/sh+7,500$3,7507,500 total
    Exercise: $0.70From: 2018-03-06Exp: 2020-09-06Common Stock (7,500 underlying)
  • Other

    Series A Warrants

    2018-03-06$0.50/sh+2,500$1,2502,500 total
    Exercise: $0.60From: 2018-03-06Exp: 2019-03-06Common Stock (2,500 underlying)

Documents

1 file
  • 4
    f4030618oloughlin_actinium.xmlPrimary

    OWNERSHIP DOCUMENT